Disease | neuropathy, peripheral |
Symptom | C0423716|neuropathic pain |
Sentences | 28 |
PubMedID- 20236533 | In mice with established neuropathic pain due to diabetic peripheral neuropathy, neither intranasal/intraperitoneal cannabidiol nor sr144528 had any effect upon already present and chronic thermal hypersensitivity or tactile allodynia (figure 7). |
PubMedID- 23186035 | A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. |
PubMedID- 20113408 | Objective: to determine the utility of substitution of pregabalin (pgb) for gabapentin (gbp) therapy in the relief of neuropathic pain (nep) in patients with peripheral neuropathy (pn). |
PubMedID- 25272094 | Pregabalin has been shown to be a safe, effective treatment for neuropathic pain associated with painful diabetic peripheral neuropathy (dpn) or postherpetic neuralgia (phn), with average time to reduction in pain of 2 days. |
PubMedID- 21166852 | Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. |
PubMedID- 26322641 | Radiprodil is an nr2b-selective nmda receptor antagonist which reached phase 2 for the treatment of neuropathic pain associated with diabetic peripheral neuropathy, but was stopped due to a lack of significant reduction in daily pain scores . |
PubMedID- 24797167 | In doing so, we considered that the only peripheral neuropathies invariably associated with neuropathic pain are mononeuritis multiplex and small-fiber neuropathies. |
PubMedID- 25503082 | Background and objective: data from two similarly designed studies of tapentadol extended release (er) for managing neuropathic pain associated with diabetic peripheral neuropathy (dpn; nct00455520, nct01041859) in adults were pooled for this analysis, allowing a detailed evaluation of efficacy in patient subgroups and secondary endpoints. |
PubMedID- 24294303 | These include neuropathic pain associated with diabetic peripheral neuropathy, fibromyalgia, chronic low back pain, and osteoarthritis knee pain (oakp). |
PubMedID- 22172451 | Perspective: this article validates a model that describes the qualities of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia. |
PubMedID- 21713059 | Pregabalin (lyrica) is a second-generation compound structurally related to gabapentin and approved in the us for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, and as adjunctive therapy for adults with partial onset seizures and for generalized anxiety disorder (gad). |
PubMedID- 21197308 | An open-label, non-randomized comparison of venlafaxine and gabapentin as monotherapy or adjuvant therapy in the management of neuropathic pain in patients with peripheral neuropathy. |
PubMedID- 24385423 | Background: duloxetine is a balanced serotonin and noradrenaline reuptake inhibitor licensed for the treatment of major depressive disorders, urinary stress incontinence and the management of neuropathic pain associated with diabetic peripheral neuropathy. |
PubMedID- 25135385 | Tapentadol prolonged release (pr) is approved in europe for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics , and in the united states (tapentadol extended release) for the management of moderate to severe, chronic pain, and neuropathic pain associated with diabetic peripheral neuropathy in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time . |
PubMedID- 24348072 | Duloxetine (cymbalta®; eli lilly and company, indianapolis, in, usa) is an snri that is approved by the us food and drug administration (fda) for the treatment of major depressive disorder and generalized anxiety disorder and the management of neuropathic pain associated with diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain associated with osteoarthritis and chronic low back pain. |
PubMedID- 21087411 | An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. |
PubMedID- 22745903 | Nearly 70 percent of those with diabetes have diabetic peripheral neuropathy, which can lead to severe neuropathic pain of the distal extremities. |
PubMedID- 26141332 | Easily defined clinical patterns of involvement are used to identify patients in need of neurologic consultation, the yield of laboratory and other diagnostic testing is reviewed for the evaluation of length-dependent, sensorimotor peripheral neuropathies (the most common form of neuropathy), and an algorithmic approach with dosing recommendations is provided for the treatment of neuropathic pain associated with peripheral neuropathy. |
PubMedID- 25969689 | All diabetic rats which showed the blood sugar level more than 250 mg·dl−1 were selected for further study by inducing peripheral neuropathy with neuropathic pain by using the chronic constriction injury (cci) of sciatic nerve . |
PubMedID- 21178594 | Objectives: the aim of this study was to examine whether the intensity of dynamic mechanical allodynia and spontaneous ongoing pain in patients with neuropathic pain associated with peripheral neuropathy was influenced by an intravenous infusion of the 5ht3-antagonist, ondansetron. |
PubMedID- 23937282 | Objectives: to compare adverse effects, tolerability and efficacy of the tricyclic antidepressants (tcas) amitriptyline and nortriptyline in management of neuropathic pain due to peripheral neuropathy (pn). |
PubMedID- 19674790 | peripheral neuropathy (pn), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. |
PubMedID- 25556685 | peripheral neuropathy can lead to neuropathic pain in a subset of patients. |
PubMedID- 20373255 | Avanir pharmaceuticals inc, under license from irisys research & development, is developing avp-923 (zenvia, neurodex) for the treatment of pseudobulbar affect (pba; in collaboration with medison pharma ltd) and neuropathic pain associated with diabetic peripheral neuropathy. |
PubMedID- 21353106 | Conclusion: flexible-dose pregabalin (150-600 mg/d for 8 weeks) was associated with a significant, although modest, reduction in mean dprs score; an improvement in anxiety and subjective sleep; and generally good tolerability compared with placebo in these korean patients with neuropathic pain due to diabetic peripheral neuropathy, postherpetic neuralgia, or posttraumatic neuropathic pain. |
PubMedID- 20487048 | Methods: a prospective, multicentre, open-label, non-comparative study included patients age >or= 18 years diagnosed with neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathic pain (pnp), or human immunodeficiency virus-related pnp. |
PubMedID- 21569381 | neuropathic pain associated with peripheral neuropathy can manifest as severe and intractable pain. |
PubMedID- 23771401 | A number of agents from diverse pharmacological classes are used to treat neuropathic pain associated with diabetic peripheral neuropathy. |
Page: 1